Therapeutic targets in the biology of Alzheimer's disease

Current Opinion in Psychiatry

Volumn 14, Issue 4, 2001, Pages 341-348

  Bush, A I ^a  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID; AMYLOID BETA PROTEIN; ANTIINFLAMMATORY AGENT; BETA SECRETASE; CHOLINESTERASE INHIBITOR; GAMMA SECRETASE; HYDROGEN PEROXIDE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; METAL COMPLEX; METALLOPROTEINASE INHIBITOR; PROTEIN; SYNTHETIC PEPTIDE; VACCINE;

ALZHEIMER DISEASE; CHEMICAL ANALYSIS; DISEASE ASSOCIATION; NEOCORTEX; NEUROTOXICITY; REVIEW; TRANSGENIC MOUSE; VACCINATION;

EID: 0034917796     PISSN: 09517367     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001504-200107000-00018     Document Type: Review

References (58)

1. A mutation in the amyloid precursor protein associated with hereditary Alzheimer's disease
2. Alzheimer's disease: Initial report of the purification and characterization of a hover cerebrovascular amyloid protein
3. Neurotrophic and neurotoxic effects of amyloid β protein: Reversal by tachykinin neuropeptides
4. An increased percentage of long amyloid β protein secreted by familial amyloid β protein precursor (beta APP717) mutants
5. Secreted amyloid β-protein similar to that in the senile plaques of Alzheimer's disease is increased in vivo by the presenilin 1 and 2 and APP mutations linked to familial Alzheimer's disease
6. Characterization of β-amyloid peptide from human cerebrospinal fluid
7. Neuronal origin of a cerebral amyloid: Neurofibrillary tangles of Alzheimer's disease contain the same protein as the amyloid of plaque cores and blood vessels
8. The precursor of Alzheimer's disease amyloid A4 protein resembles a cell-surface receptor
9. Aggregation and secondary structure of synthetic amyloid β A4 peptides of Alzheimer's disease
10. The carboxy terminus of the β amyloid protein is critical for the seeding of amyloid formation: Implications for the pathogenesis of Alzheimer's disease
11. Characterization of copper interactions with Alzheimer Aβ peptides: Identification of an attomolar affinity copper binding site on Aβ1-42
12. Soluble pool of Aβ amyloid as a determinant of severity of neurodegeneration in Alzheimer's disease
13. The levels of soluble versus insoluble brain Aβ distinguish Alzheimer's disease from normal and pathologic aging
14. Soluble amyloid beta peptide concentration as a predictor of synaptic change in Alzheimer's disease
15. Evidence that the beta-amyloid plaques of Alzheimer's disease represent the redox-silencing and entombment of Aβ by zinc
16. Mutation of the Alzheimer's disease amyloid gene in hereditary cerebral hemorrhage, Dutch type
17. Age related CNS disorder and early death in transgenic FVB/N mice overexpressing Alzheimer amyloid precursor proteins
18. Mutations in Cu/Zn superoxide dismutase gene are associated with familial amyotrophic lateral sclerosis
19. Alzheimer's disease amyloid-β binds Cu and Zn to generate an allosterically-ordered membrane-penetrating structure containing SOD-like subunits
20. Treatment with a copper-zinc chelator markedly and rapidly inhibits β-amyloid accumulation in Alzheimer's disease transgenic mice
21. Immunization with amyloid-beta attenuates Alzheimer-disease-like pathology in the PDAPP mouse
22. Peripherally administered antibodies against amyloid beta-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease
23. Nasal administration of amyloid-beta peptide decreases cerebral amyloid burden in a mouse model of Alzheimer's disease
24. Aβ peptide vaccination prevents memory loss in an animal model of Alzheimer's disease
25. Aβ peptide immunization reduces behavioural impairment and plaques in a model of Alzheimer's disease
26. A learning deficit related to age and beta-amyloid plaques in a mouse model of Alzheimer's disease
27. Copper levels are increased in the cerebral cortex and liver of APP and APLP2 knockout mice
28. Alzheimer Aβ functions as a superoxide antioxidant in vitro and in vivo
29. Beta-secretase cleavage of Alzheimer's amyloid precursor protein by the transmembrane aspartic protease BACE
30. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity
31. Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1
32. Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1
33. BACE1 is the major beta-secretase for generation of Abeta peptides by neurons
34. Mice deficient in BACE1, the Alzheimer's beta-secretase, have normal phenotype and abolished beta-amyloid generation
35. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain
36. Neurobiology of zinc and zinc-containing neurons
37. Rapid induction of Alzheimer Aβ amyloid formation by zinc
38. Dramatic aggregation of Alzheimer Aβ by Cu(II) is induced by conditions representing physiological acidosis
39. Aqueous dissolution of Alzheimer's disease Aβ amyloid deposits by biometal depletion
40. The Aβ peptide of Alzheimer's disease directly produces hydrogen peroxide through metal ion reduction
41. Cu(II) potentiation of Alzheimer Aβ neurotoxicity: Correlation with cell-free hydrogen peroxide production and metal reduction
42. In situ oxidative catalysis by neurofibrillary tangles and senile plaques in Alzheimer's disease: A central role for bound transition metals
43. Copper, iron and zinc in Alzheimer's disease senile plaques
44. Histological evidence implicating zinc in Alzheimer's disease
45. Histochemically reactive zinc in plaques of the Swedish mutant beta-amyloid precursor protein transgenic mice
46. Induction of nitric oxide-dependent apoptosis in motor neurons by zinc-deficient superoxide dismutase
47. Modulation of Aβ adhesiveness and secretase site cleavage by zinc
48. Histidine-13 is a crucial residue in the zinc ion-induced aggregation of the Aβ peptide of Alzheimer's disease
49. Metal binding modes of Alzheimer's amyloid β-peptide in insoluble aggregates and soluble complexes
50. Anti-inflammatory drugs protect against Alzheimer disease at low doses
51. Effect of anti-inflammatory medications on neuropathological findings in Alzheimer disease
52. A double-blind, placebo-controlled trial of diclofenac/misoprostol in Alzheimer's disease
53. Ibuprofen suppresses plaque pathology and inflammation in a mouse model for Alzheimer's disease
54. Antiinflammatory effects of estrogen on microglial activation
55. Estrogen enhances uptake of amyloid beta-protein by microglia derived from the human cortex
56. Estrogen for Alzheimer's disease in women: Randomized, double-blind, placebo-controlled trial
57. Decreased prevalence of Alzheimer disease associated with 3-hydroxy-3-methyglutaryl coenzyme A reductase inhibitors
58. Simvastatin strongly reduces levels of Alzheimer's disease beta-amyloid peptides Abeta 42 and Abeta 40 in vitro and in vivo